Serve as the senior Early S&E leader within the TALT, influencing therapeutic strategy and ensuring external innovation priorities are integrated into portfolio planning.
Lead proactive sourcing and scouting efforts for preclinical and Phase 1 assets, building a robust pipeline of opportunities aligned with TA strategy.
Co-lead internal meetings (with Late Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas.
Develop and execute early partnering strategies, including onboarding approaches and competitive positioning for priority assets.
Drive cross-functional due diligence for each opportunity, coordinating scientific, clinical, regulatory, and commercial assessments to inform governance decisions.
Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close.
Represent the TA externally, leading sourcing activities at specialized conferences and cultivating relationships with biotech, academia, and investment communities.

Significant tenure in biopharma with significant experience in external innovation, search & evaluation, or business development.
Advanced degree required (PhD, MD, or equivalent).
Deep scientific expertise in Hematology or Cardiovascular/Renal therapeutic areas.
Proven track record of leading due diligence and closing early-stage deals.
Strong network within biotech, academia, and pharma BD organizations.

Director, Search & Evaluation – Early TA Lead

Key skills